RK-287107 manufacturers
- RK-287107
-
- $57.00 / 1mg
-
2024-11-19
- CAS:2171386-10-8
- Min. Order:
- Purity: 99.59%
- Supply Ability: 10g
|
| | RK-287107 Basic information |
| Product Name: | RK-287107 | | Synonyms: | RK-287107;RK287107;RK 287107;4(3H)-Quinazolinone, 2-[4,6-difluoro-1-(2-hydroxyethyl)spiro[3H-indole-3,4'-piperidine]-1'(2H)-yl]-5,6,7,8-tetrahydro-;inhibit,poly ADP ribose polymerase,RK287107,RK-287107,PARP,RK 287107,Inhibitor;RK-287107, 10 mM in DMSO | | CAS: | 2171386-10-8 | | MF: | C22H26F2N4O2 | | MW: | 416.46 | | EINECS: | | | Product Categories: | | | Mol File: | 2171386-10-8.mol |  |
| | RK-287107 Chemical Properties |
| Boiling point | 602.5±65.0 °C(Predicted) | | density | 1.48±0.1 g/cm3(Predicted) | | storage temp. | 4°C, protect from light | | solubility | DMSO: soluble | | form | A solid | | pka | 14.24±0.10(Predicted) | | color | White to off-white |
| | RK-287107 Usage And Synthesis |
| Uses | RK-287107 is a potent and specific tankyrase inhibitor with IC50s of 14.3 and 10.6 nM for tankyrase-1 and tankyrase-2, respectively. RK-287107 blocks colorectal cancer cell growth[1]. | | in vivo | RK-287107 (100 and 300 mg/kg; i.p. administration; once per day; 5-days on/ 2-days off schedule for 2 weeks) inhibits tumor growth in a mouse xenograft model[1]. | Animal Model: | 6-week-old female NOD.CB17-Prkdcscid/J mice with colorectal cancer COLO-320DM[1] | | Dosage: | 100 and 300 mg/kg | | Administration: | Administration i.p.; once per day; 5-days on/ 2-days off schedule for 2 weeks | | Result: | 100 and 300 mg/kg resulted in 32.9% and 44.2% TGI, respectively. |
| | IC 50 | tankyrase-1: 14.3 nM (IC50); tankyrase-2: 10.6 nM (IC50) | | References | [1] Mizutani A, et al. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model. Cancer Sci. 2018 Dec;109(12):4003-4014. DOI:10.1111/cas.13805 |
| | RK-287107 Preparation Products And Raw materials |
|